Zim Laboratories Reports Negative Financial Results, Receives 'Strong Sell' Rating from MarketsMOJO

Zim Laboratories, a microcap pharmaceutical company, recently declared its financial results for the quarter ending September 2024. The company's stock has been given a 'Strong Sell' rating by MarketsMOJO.

According to the financial report, Zim Laboratories has seen a negative performance in the second quarter of the fiscal year 2024-2025. The company's score has fallen from -14 to -18 in the last three months.

The financials also show a decline in the company's profit before tax (PBT) and profit after tax (PAT) by -59.20% and -42.7% respectively, compared to the same period last year. The trend for both PBT and PAT is expected to continue in the near term.

Additionally, Zim Laboratories' interest costs have increased by 44.47% in the last six months, indicating a rise in borrowings. The company's operating cash flow has also been consistently falling over the past three years.

Furthermore, the company's non-operating income is 44.59% of its PBT, which suggests that a significant portion of its profits are coming from non-business activities, which may not be sustainable in the long run.

Overall, Zim Laboratories' financial performance for the quarter ending September 2024 has been negative, leading to a 'Strong Sell' recommendation from MarketsMOJO. Investors should carefully consider these factors before making any investment decisions.